Why Liquidia Corporation Shares Are Moving Lower Monday
Portfolio Pulse from Dylan Berman
Liquidia Corporation's stock fell over 33% after the FDA granted tentative approval for YUTREPIA, pending final approval in 2025. The company plans to challenge the FDA's decision to grant exclusivity to United Therapeutics for Tyvaso DPI.
August 19, 2024 | 4:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Liquidia's stock dropped over 33% due to FDA's tentative approval of YUTREPIA, with final approval pending until 2025. The company plans to challenge the FDA's decision granting exclusivity to United Therapeutics.
The significant drop in Liquidia's stock price is directly linked to the FDA's decision, which delays YUTREPIA's market entry until 2025. The company's plan to challenge the FDA's decision adds uncertainty, negatively impacting investor sentiment.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100